Kamil Ali-Jackson - Jun 3, 2021 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: Chief Legal Officer
Signature: /s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol: ACRS
Transactions as of: Jun 3, 2021
Transactions value $: -$208,421
Form type: 4
Date filed: 6/4/2021, 07:52 PM
Previous filing: Jun 2, 2021
Next filing: Jun 17, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRS	Common Stock	Sale	-$208K	-9.49K	-7.21%	$21.96	122K	Jun 3, 2021	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021.
F2	The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.57 to $22.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021.

The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.57 to $22.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.